Key statistics
On Friday, Evotec SE (EVTA:DUS) closed at 4.26, 71.77% above the 52 week low of 2.48 set on Oct 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.24 |
---|---|
High | 4.32 |
Low | 4.24 |
Bid | 4.26 |
Offer | 4.44 |
Previous close | 4.28 |
Average volume | 140.00 |
---|---|
Shares outstanding | 355.53m |
Free float | 320.12m |
P/E (TTM) | -- |
Market cap | 1.60bn USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Feb 14 2025 18:31 GMT.
More ▼
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-DD: Evotec SE: Dr. Cord Dohrmann, Exercise against Cash Settlement (Share Performance Plan)
- EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk
- EQS-PVR: Evotec SE: Correction of a release from 27/11/2024 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
More ▼